What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower.
週三，Madrigal Pharmaceuticals股票 (納斯達克: MDGL) 和Sagimet Biosciences股票 (納斯達克: SGMT) 價格走低。
At the EASL International Liver Congress 2024, Eli Lilly And Co (NYSE:LLY) shared an abstract highlighting fibrosis results from a Phase 2 trial of tirzepatide in patients with metabolic dysfunction-associated steatohepatitis (MASH).
在2024年EASL國際肝病大會上，Eli Lilly And Co股票 (紐交所: LLY) 分享了一項關於tirzepatide一期試驗中代謝紊亂相關脂肪肝炎(MASH)患者的纖維化結果的摘要。
Tirzepatide is a key ingredient in popular Mounjaro for diabetes and Zepbound for weight loss.
tirzepatide是主流幣Mounjaro和Zepbound的關鍵成分之一，用於治療糖尿病和減肥。
Other companies working on MASH candidates include 89bio Inc (NASDAQ:ETNB), Akero Therapeutics Inc (NASDAQ:AKRO), and Viking Therapeutics Inc (NASDAQ:VKTX).
其他正在研究治療MASH產品的公司包括89bio股票(納斯達克: ETNB)，Akero Therapeutics股票(納斯達克: AKRO)和Viking Therapeutics股票(納斯達克: VKTX)。
The Phase 2 SYNERGY-NASH trial studied three doses (5 mg, 10 mg or 15 mg) of tirzepatide in 190 people. End-of-treatment liver biopsies were available for 157 participants.
SYNERGY-NASH一期試驗研究了tirzepatide的3種劑量（5毫克、10毫克或15毫克）對190名患者的療效。157 名參與者末期治療時都有肝活檢報告。
The proportion of participants who achieved MASH resolution without worsening of fibrosis was 9.8% for placebo, 43.6% for 5 mg, 55.5% for 10 mg and 62.4% for 15 mg.
安慰劑組中達到MASH緩解但不加重纖維化的參與者比例爲9.8％, 5毫克組爲43.6％, 10毫克組爲55.5％，15毫克組爲62.4％。
Among 155 participants who completed the study on treatment with evaluable biopsies, the primary endpoint of MASH resolution without worsening of fibrosis was achieved by 51.8%, 62.8%, and 73.3% for tirzepatide 5 mg, 10 mg, and 15 mg, respectively, compared with 13.2% for placebo.
在接受評估肝活檢的155名患者中，5毫克、10毫克和15毫克tirzepatide組的MASH緩解率分別達到51.8％、62.8％和73.3％，安慰劑組爲13.2％。
The proportion who achieved ≥ 1-stage fibrosis improvement without worsening of MASH was 29.7% for placebo, 54.9% for tirzepatide 5 mg, 51.3% for tirzepatide 10 mg, and 51.0% for tirzepatide 15 mg.
安慰劑組中實現≥ 1級纖維化改善但不加重MASH的比例爲29.7％，5毫克組爲54.9％，10毫克組爲51.3％，15毫克組爲51.0％。
A reduction in nonalcoholic fatty liver disease activity score (NAS) by ≥ 2 points was achieved by 71.7% to 78.3% of participants across the three tirzepatide dose groups and by 36.7% with placebo. Body weight was reduced by up to 17.3% with tirzepatide.
三個tirzepatide劑量組中71.7％至78.3％的參與者降低了非酒精性脂肪肝疾病活動得分(NAS)，安慰劑組爲36.7％。tirzepatide可減輕體重長達17.3％。
Liver enzymes and fat decreased, and serum and imaging biomarkers of liver inflammation and fibrosis significantly improved in the tirzepatide groups compared to the placebo.
與安慰劑組相比，tirzepatide組的肝酶和脂肪降低，並且肝臟炎症和纖維化的血清和影像生物標誌物明顯改善。
The abstract added that there was a lack of a clear dose relationship in achieving MASH resolution without worsening the fibrosis endpoint.
摘要補充說，在實現MASH緩解且不惡化纖維化終點的劑量關係方面，沒有明確的劑量關係。
Larger and longer trials are needed to assess the efficacy and safety of tirzepatide for non-cirrhotic MASH.
需要更大規模和更長時間的試驗來評估非肝硬化型MASH的tirzepatide療效和安全性。
Related: FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring.
相關:美國FDA有條件批准Madrigal Pharmaceuticals的Resmetirom作爲脂肪肝病的首個治療藥物。
Price Action: MDGL shares are down 5.14% at $231.78, and SGMT shares are down 7.22% at $4.66 at the last check on Wednesday.
截至週三最後一次交易，MDGL股票以231.78美元下跌5.14％，SGMT股票以4.66美元下跌7.22％。
譯文內容由第三人軟體翻譯。